1. Scrip
  2. >>Business
  3. >>Strategy

At Pfizer, A Split A Decade In The Making

 
• By Jessica Merrill

Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.

Couple holding two halves of broken heart against wooden background - Image
Pfizer is breaking up the company to focus on innovative pharma

It was back in 2010, when Lipitor was edging close to losing its patent protection, that debate erupted among Pfizer Inc. investors over whether the pharma giant could unlock trapped value by splitting up the company into an innovative, R&D-focused company and a cash-generating established products business. The businesses were reorganized, the decision was considered, delayed, considered again, scrapped in 2016, and now nine years later, it is poised to happen.

Pfizer announced on 29 July that it will split off its Upjohn off-patent branded and generics business and merge it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Amgen’s ‘Stunning’ VESALIUS Results Could Push Repatha Into The Mainstream

 
• By Mandy Jackson

Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.

J&J Plans Educational Push After Darzalex Smoldering Myeloma Approval

 
• By Alaric DeArment

The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

More from Business

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Korean Biosimilars Giants Step Up Race To Become Innovators

 
• By Jung Won Shin

South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.

AstraZeneca Stays Coy On US Pricing Deal Impact

 
• By Andrew McConaghie

Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.